ABCB1 p.Met986Cys
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 19456124
[PubMed]
Crowley E et al: "Transmembrane helix 12 modulates progression of the ATP catalytic cycle in ABCB1."
No.
Sentence
Comment
67
This necessitated the centrifugation (100000g for 30 min) of 500 μL Table 1: Mutagenic Oligonucleotide Primers Used To Generate TM12 Mutationsa mutation primer sequence (50 -30 ) diagnostic restriction digest L976C GAGGATGTTCTAtgtGTATTTTCAGCTGTTG -SpeI F978C GTTCTACTAGTATgTTCtGCaGTTGTCTTTGGTG +PstI A980C CTACTAGTATTTTCAtgcGTTGTCTTTGGTGCCATGGCC -PvuII V982C CTAGTATTTTCAGCgGTTtgCTTTGGTGCCATGGCC -PvuII G984C GCTGTTGTCTTTtGTGCtATGGCCGTGG -NcoI M986C GTATTTGGTGCttgtGCtGTGGGGCAAGTC -NcoI V988C GGTGCCATGGCCtgtGGGCAAGTCAGTTC -BstXI G989C CTTTGGTGCCATGGCCGTGtGcCAAGTCAGTTCATTTGC +BstXI Q990C GGCCGTGGGGtgtGTCtcTTCATTTGCTCC +EarI a Primer sequences contain an introduced cysteine residue (bold) and additional silent mutations (lower case), with respect to the coding sequence that generates or removes the indicated restriction site.
X
ABCB1 p.Met986Cys 19456124:67:450
status: NEW108 Panels B and C of Figure 2 show a time course of proteolytic digestion of the purified, reconstituted Cys-less and M986C proteins.
X
ABCB1 p.Met986Cys 19456124:108:115
status: NEW127 Proteolysis of purified, reconstituted Cys-less (B) and M986C (C) was carried out in the presence of 0.5 μg of bovine pancreatic trypsin.
X
ABCB1 p.Met986Cys 19456124:127:56
status: NEW155 Table 2: Potency and Degree of Drug Stimulation of ATP Hydrolysis by ABCB1a nicardipine vinblastine EC50 (μM) fold stimulation EC50 (μM) fold stimulation Cys-less 4.1 ( 1.1 4.0 ( 0.6 5.91 ( 2.9 2.2 ( 0.2 L976C 5.2 ( 0.2 7.4 ( 1.4 10.0 ( 0.0 3.5 ( 0.6 F978C 24.1 ( 2.3b 9.5 ( 1.4 42.9 ( 4.3b 2.3 ( 0.5 A980C 3.4 ( 0.3 5.1 ( 0.9 12.3 ( 1.8 3.2 ( 0.8 V982C 5.8 ( 0.9 4.2 ( 0.5 2.0 ( 0.7 1.8 ( 0.2 G984C 37.6 ( 11.2b 16.2 ( 6.6b 6.7 ( 1.7 6.2 ( 2.3 M986C 9.2 ( 0.8 4.7 ( 1.1 15.0 ( 2.0b 2.8 ( 0.7 V988C 3.9 ( 0.6 3.1 ( 0.1 7.3 ( 2.3 1.9 ( 0.2 G989C 13.6 ( 1.5 5.1 ( 1.6 4.9 ( 0.9 2.4 ( 0.3 Q990C 6.9 ( 1.1 3.7 ( 1.0 NDc NDc S992C 4.9 ( 0.5 4.2 ( 0.6 7.1 ( 2.6 2.3 ( 0.4 F994C 1.7 ( 0.4 3.2 ( 0.8 5.9 ( 2.5 1.6 ( 0.3 a ATPase activity was plotted as a function of the drug concentration and potency (EC50) and degree of stimulation obtained by nonlinear regression of the dose-response relationship equation.
X
ABCB1 p.Met986Cys 19456124:155:457
status: NEW159 M986C isoforms (Table 2).
X
ABCB1 p.Met986Cys 19456124:159:0
status: NEW161 In contrast, for the M986C isoform, the effects of nicardipine were similar to cysteine-less ABCB1, while the potency of vinblastine was significantly (p<0.05) reduced.
X
ABCB1 p.Met986Cys 19456124:161:21
status: NEW
PMID: 20731718
[PubMed]
Crowley E et al: "Transmembrane helix 12 plays a pivotal role in coupling energy provision and drug binding in ABCB1."
No.
Sentence
Comment
55
Labelling of each isoform was analysed by densitometry and plotted as a function of time, as shown for the M986C isoform for the three probes in Fig. 2A.
X
ABCB1 p.Met986Cys 20731718:55:107
status: NEW56 Nonlinear regression of the exponential reaction curve estimated that the maximum extent of labelling for the representative curve of the M986C isoform in the basal state was 78% for CM (t1 / 2 = 8 min), 59% for BM (t1 / 2 = 4 min) and 23% for FM (t1 / 2 = 45 min).
X
ABCB1 p.Met986Cys 20731718:56:138
status: NEW61 The central region of TM12, from V982C to M986C, displayed the highest extent of labelling, with Lext values of 75-100%.
X
ABCB1 p.Met986Cys 20731718:61:42
status: NEW79 A similar stretch of TM12 (namely V982C-V988C) displayed the greatest propensity to be labelled with BM, with only isoform M986C being not completely labelled by the probe.
X
ABCB1 p.Met986Cys 20731718:79:123
status: NEW92 However, two residues (G984C and M986C) in the central region of TM12 did display labelling above background, albeit with Lext values of approximately 20%.
X
ABCB1 p.Met986Cys 20731718:92:33
status: NEW94 The rapid kinetics of labelling of M986C with both BM and FM would also support this local increase in hydrophilicity.
X
ABCB1 p.Met986Cys 20731718:94:35
status: NEW105 (A) Representative data for labelling of the M986C isoform with CM ( ), FM (d) and BM (s).
X
ABCB1 p.Met986Cys 20731718:105:45
status: NEW139 Mutant CM BM FM Lext (%) t1 / 2 (min) Lext (%) t1 / 2 (min) Lext (%) t1 / 2 (min) L976C 38 ± 5 29 ± 12 66 ± 14 29 ± 18 - - A980C 53 ± 6 34 ± 1 54 ± 8 20 ± 9 - - V982C 98 ± 14 15 ± 6 164 ± 50 27 ± 17 - - G984C 73 ± 14 29 ± 6 84 ± 24 22 ± 7 13 ± 10 ND M986C 89 ± 30 25 ± 10 51 ± 5 3 ± 2 21 ± 2 ND V988C 53 ± 6 37 ± 18 221 ± 63 18 ± 12 - - G989C 64 ± 7 15 ± 6 21 ± 3 9 ± 2 - - S992C 55 ± 4 22 ± 6 51 ± 5 4 ± 1 32 ± 3 25 ± 5 F994C 51 ± 10 11 ± 9 111 ± 35 13 ± 10 129 ± 24 8 ± 3 Conformational changes - central region Two of the residues examined in the central region (G984C and M986C) of TM12 have been shown to accommodate partial labelling with FM, suggestive of aqueous accessibility in the basal state. At M986C, the extent of labelling with the hydrophilic probe was increased following the addition of nonhydrolysable nucleotide.
X
ABCB1 p.Met986Cys 20731718:139:335
status: NEWX
ABCB1 p.Met986Cys 20731718:139:787
status: NEWX
ABCB1 p.Met986Cys 20731718:139:919
status: NEW143 G984C underwent a broadly similar shift in topography as M986C, although the degree of alteration was somewhat less striking.
X
ABCB1 p.Met986Cys 20731718:143:57
status: NEW164 ABCB1 isoform Catalytic intermediate CM BM FM L976C Basal ++ +++ ) AMP-PNP +++ ++ ) Vi trapped +++ +++ ) A980C Basal ++ ++ ) AMP-PNP +++ + ) Vi trapped +++ +++ ) V982C Basal +++ +++ ) AMP-PNP +++ +++ ) Vi trapped +++ +++ ) G984C Basal +++ +++ + AMP-PNP +++ +++ + Vi trapped +++ ++ ) M986C Basal +++ ++ + AMP-PNP ++ +++ ++ Vi trapped +++ ++ ) V988C Basal ++ +++ ) AMP-PNP +++ +++ ) Vi trapped +++ +++ ) G989C Basal ++ + ) AMP-PNP ++ ++ ) Vi trapped ++ + ) S992C Basal ++ ++ + AMP-PNP +++ +++ ++ Vi trapped ++ ++ + F994C Basal ++ +++ +++ AMP-PNP ++ +++ ++ Vi trapped +++ +++ + reflect localization at the membrane-solute interface.
X
ABCB1 p.Met986Cys 20731718:164:283
status: NEW191 M986C and S992C (Fig. 3) on TM12 straddle the boundaries of this hydrophilic band, and also face directly into the presumed translocation pore.
X
ABCB1 p.Met986Cys 20731718:191:0
status: NEW
PMID: 9261097
[PubMed]
Loo TW et al: "Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12."
No.
Sentence
Comment
68
To test these predictions, we introduced pairs of cysteines into a Cys-less mutant of P-glycoprotein to create the mutants F336C/S979C, L339C/V982C, F343C/M986C, G346C/G989C, and P350C/S993C.
X
ABCB1 p.Met986Cys 9261097:68:155
status: NEW76 Fig. 1D shows that a product with reduced mobility on SDS-PAGE gels was present when mutants F343C/M986C, G346C/G989C, and P350C/ S993C were treated with oxidant.
X
ABCB1 p.Met986Cys 9261097:76:99
status: NEW100 The effect of nucleotides on cross-linking was also tested on mutants F343C/M986C, G346C/G989C, and P350C/S993C.
X
ABCB1 p.Met986Cys 9261097:100:76
status: NEW103 To test the effect of drug substrates, cross-linking of mutants L332C/L975C, F343C/M986C, G346C/G989C, and P350C/ S993C was done in the presence of verapamil, cyclosporin A, vinblastine, or colchicine.
X
ABCB1 p.Met986Cys 9261097:103:83
status: NEW105 By contrast, all the drug substrates were effective in blocking cross-linking of mutants F343C/M986C and G346C/G989C (Fig. 3, B and C), but were less effective in preventing cross-linking of mutant P350C/S993C (Fig. 3D).
X
ABCB1 p.Met986Cys 9261097:105:95
status: NEW108 Effect of Cross-linking on Drug-stimulated ATPase Activity- Mutants L332C/L975C, F343C/M986C, G346C/G989C, and P350C/S993C were still active since they retained about 90, 30, 10, and 70%, respectively, of the verapamil-stimulated ATPase activity of the Cys-less P-glycoprotein.
X
ABCB1 p.Met986Cys 9261097:108:87
status: NEW109 Cross-linking of mutants F343C/M986C, G346C/G989C, and P350C/S993C, but not L332C/L975C, was reversed by treatment with dithiothreitol (Fig. 4A).
X
ABCB1 p.Met986Cys 9261097:109:31
status: NEW126 Membranes prepared from HEK 293 cells expressing mutants L332C/L975C (A), F343C/M986C (B), G346C/G989C (C), and P350/S993C (D) were treated without (-) or with (ϩ) 2 mM (A) or 0.2 mM (B-D) copper phenanthroline for 10 min at 37 °C in the presence of 5 mM ATP, 5 mM ATP plus 0.2 mM sodium vanadate, 5 mM ADP, 5 mM ADP plus 0.2 mM sodium vanadate, or 5 mM AMP-PNP.
X
ABCB1 p.Met986Cys 9261097:126:80
status: NEW132 Membranes prepared from HEK 293 cells expressing mutants L332C/ L975C (A), F343C/M986C (B), G346C/G989C (C), and P350/S993C (D) were treated without (-) or with (ϩ) 2 mM (A) or 0.2 mM (B-D) copper phenanthroline for 10 min at 37 °C in the presence of 1 mM verapamil, 0.1 mM vinblastine, 50 M cyclosporin A, or 5 mM colchicine.
X
ABCB1 p.Met986Cys 9261097:132:81
status: NEW144 Drug substrates inhibited cross-linking of mutants F343C/ M986C, G346C/G989C, and P350C/S993C.
X
ABCB1 p.Met986Cys 9261097:144:58
status: NEW
PMID: 9405384
[PubMed]
Loo TW et al: "Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate."
No.
Sentence
Comment
141
Cross-linking between residues F343C/M986C, G346C/G989C, and P350C/S993C was prevented by the presence of drug substrates.
X
ABCB1 p.Met986Cys 9405384:141:37
status: NEW
No.
Sentence
Comment
204
Four cross-linked pairs, namely L332C/L975C, F343C/M986C, G346C/G989C and P350C/S993C, were generated in separate mutant molecules.
X
ABCB1 p.Met986Cys 9841738:204:51
status: NEW